Cartesian Therapeutics' Q1 Revenue Plummets 93%, Losses Widen Amid R&D Push
RNAC sits 22% above its 52-week low of $5.6.
Summary
Cartesian Therapeutics reported Q1 2026 revenue of $78K, a sharp 92.9% year-over-year decrease, alongside a net loss of $39.18 million, resulting in an EPS of ($1.46), significantly wider than the ($0.68) loss per share in the prior year quarter. This earnings report provides the first financial update for 2026, following the company's substantial 2025 net loss of $130.3 million. The widening losses reflect increased R&D investment to fund late-stage clinical activity, including the advancement of Descartes-08 into Phase 3 for myasthenia gravis. The substantial decline in revenue and widening net loss indicate a significant cash burn, which is critical for a clinical-stage biotech company. Traders will closely monitor the company's stated cash runway of at least 12 months and any further financing activities, especially given the reliance on an at-the-market equity program.
At the time of this announcement, RNAC was trading at $6.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.5M. The 52-week trading range was $5.60 to $15.57. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.